West Pharmaceutical Services Inc (WST) stock
WSTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3032% above fair value
$416.42+5.12 (+1.24%)
Close on Nov 13, 2026Market cap $29.01BP/E 46.7Yield 0.21%
West Pharmaceutical Services r&d expenses
Research and development expenses are spending on new products and technology.
West Pharmaceutical Services's R&D Expenses for the twelve months ending Sep 30, 2026 was $75.60M, up 6.5% year over year. For fiscal 2025 it was $74.30M, up 7.5% from the year before. Over ten years it grew 8.1% a year on average. The highest annual figure on record is $74.30M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.30M | +7.5% |
| FY2024 | Dec 31, 2024 | $69.10M | +1.0% |
| FY2023 | Dec 31, 2023 | $68.40M | +16.9% |
| FY2022 | Dec 31, 2022 | $58.50M | +10.8% |
| FY2021 | Dec 31, 2021 | $52.80M | +12.6% |
| FY2020 | Dec 31, 2020 | $46.90M | +20.6% |
| FY2019 | Dec 31, 2019 | $38.90M | -3.5% |
| FY2018 | Dec 31, 2018 | $40.30M | +3.1% |
| FY2017 | Dec 31, 2017 | $39.10M | +6.3% |
| FY2016 | Dec 31, 2016 | $36.80M | +7.9% |
| FY2015 | Dec 31, 2015 | $34.10M | -8.6% |
| FY2014 | Dec 31, 2014 | $37.30M | -1.6% |
| FY2013 | Dec 31, 2013 | $37.90M | +14.2% |
| FY2012 | Dec 31, 2012 | $33.20M | +14.1% |
| FY2011 | Dec 31, 2011 | $29.10M | +21.8% |
| FY2010 | Dec 31, 2010 | $23.90M | +20.1% |
| FY2009 | Dec 31, 2009 | $19.90M | +6.4% |
| FY2008 | Dec 31, 2008 | $18.70M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $18.30M | +7.0% |
| Q2 FY2026 | Jun 30, 2026 | $19.70M | +3.1% |
| Q1 FY2026 | Mar 31, 2026 | $15.80M | -3.1% |
| Q4 FY2025 | Dec 31, 2025 | $21.80M | +17.8% |
| Q3 FY2025 | Sep 30, 2025 | $17.10M | +10.3% |
| Q2 FY2025 | Jun 30, 2025 | $19.10M | +9.1% |
| Q1 FY2025 | Mar 31, 2025 | $16.30M | -7.4% |
| Q4 FY2024 | Dec 31, 2024 | $18.50M | +0.5% |
| Q3 FY2024 | Sep 30, 2024 | $15.50M | -5.5% |
| Q2 FY2024 | Jun 30, 2024 | $17.50M | +6.1% |
| Q1 FY2024 | Mar 31, 2024 | $17.60M | +2.9% |
| Q4 FY2023 | Dec 31, 2023 | $18.40M | +15.7% |
| Q3 FY2023 | Sep 30, 2023 | $16.40M | +20.6% |
| Q2 FY2023 | Jun 30, 2023 | $16.50M | +14.6% |
| Q1 FY2023 | Mar 31, 2023 | $17.10M | +17.1% |
| Q4 FY2022 | Dec 31, 2022 | $15.90M | +16.1% |
| Q3 FY2022 | Sep 30, 2022 | $13.60M | +3.8% |
| Q2 FY2022 | Jun 30, 2022 | $14.40M | +4.3% |
| Q1 FY2022 | Mar 31, 2022 | $14.60M | +19.7% |
| Q4 FY2021 | Dec 31, 2021 | $13.70M | +6.2% |
| Q3 FY2021 | Sep 30, 2021 | $13.10M | +4.8% |
| Q2 FY2021 | Jun 30, 2021 | $13.80M | +27.8% |
| Q1 FY2021 | Mar 31, 2021 | $12.20M | +14.0% |
| Q4 FY2020 | Dec 31, 2020 | $12.90M | +26.5% |
| Q3 FY2020 | Sep 30, 2020 | $12.50M | +34.4% |
| Q2 FY2020 | Jun 30, 2020 | $10.80M | +12.5% |
| Q1 FY2020 | Mar 31, 2020 | $10.70M | +9.2% |
| Q4 FY2019 | Dec 31, 2019 | $10.20M | +4.1% |
| Q3 FY2019 | Sep 30, 2019 | $9.30M | -7.9% |
| Q2 FY2019 | Jun 30, 2019 | $9.60M | -11.1% |
| Q1 FY2019 | Mar 31, 2019 | $9.80M | +2.1% |
| Q4 FY2018 | Dec 31, 2018 | $9.80M | +1.0% |
| Q3 FY2018 | Sep 30, 2018 | $10.10M | +11.0% |
| Q2 FY2018 | Jun 30, 2018 | $10.80M | +8.0% |
| Q1 FY2018 | Mar 31, 2018 | $9.60M | -6.8% |
| Q4 FY2017 | Dec 31, 2017 | $9.70M | +1.0% |
| Q3 FY2017 | Sep 30, 2017 | $9.10M | – |
| Q2 FY2017 | Jun 30, 2017 | $10.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $10.30M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.60M | – |
See a number that looks wrong?